➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Baxter
Colorcon
Mallinckrodt
AstraZeneca

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for IRX-5183


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for IRX-5183?

IRX-5183 is an investigational drug.

There have been 10 clinical trials for IRX-5183. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Squamous Cell, Carcinoma, and Head and Neck Neoplasms. The leading clinical trial sponsors are IRX Therapeutics, National Cancer Institute (NCI), and Providence Health & Services.

There are six US patents protecting this investigational drug and fifty-four international patents.

Recent Clinical Trials for IRX-5183
TitleSponsorPhase
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerBrooklyn ImmunoTherapeutics, LLCPhase 2
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerMerck Sharp & Dohme Corp.Phase 2
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerProvidence Health & ServicesPhase 2

See all IRX-5183 clinical trials

Clinical Trial Summary for IRX-5183

Top disease conditions for IRX-5183
Top clinical trial sponsors for IRX-5183

See all IRX-5183 clinical trials

US Patents for IRX-5183

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IRX-5183   Start Trial Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Syros Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
IRX-5183   Start Trial Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Syros Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
IRX-5183   Start Trial RAR selective agonists in combination with immune modulators for cancer immunotherapy Io Therapeutics, Inc. (Almeda, TX)   Start Trial
IRX-5183   Start Trial Treatment of tumors with RAR.alpha. selective retinoid compounds in combination with other anti-tumor agents Allergan Sales, Inc. (Irvine, CA)   Start Trial
IRX-5183   Start Trial Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Syros Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IRX-5183

Drugname Country Document Number Estimated Expiration Related US Patent
IRX-5183 Australia 2016243702 2035-03-31   Start Trial
IRX-5183 Brazil 112017020745 2035-03-31   Start Trial
IRX-5183 Canada 2981518 2035-03-31   Start Trial
IRX-5183 China 107613969 2035-03-31   Start Trial
IRX-5183 European Patent Office 3277272 2035-03-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Colorcon
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.